Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart in SSc-ILD
NCT05270668Phase 2Active, not recruiting
- Sponsor
- Prometheus Biosciences
- Start
- Mar 2022
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 2 trial of tulisokibart in systemic sclerosis (SSc), interstitial lung disease (ILD), sponsored by Prometheus Biosciences. Started Mar 2022; status: active, not recruiting.
02
Drugs
tulisokibart
03
Conditions
systemic sclerosis (SSc)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05270668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270668.